Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972879 | 1.00 | KMT2A (0.71) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL10672193 | 0.89 | KMT2A (0.70) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL10673281 | 0.88 | MEN1 (0.65) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL10671563 | 0.86 | KMT2A (0.65) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL4507476 | 0.86 | MEN1 (0.53) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL7612454 | 0.84 | MEN1 (0.52) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL15190559 | 0.84 | MEN1 (0.51) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL8144841 | 0.84 | MEN1 (0.51) | KMT2AMEN1PGRALDH1A1KDM4E | |
| Paquinimod SCHEMBL1573633 | 0.83 | MEN1 (0.50) | KMT2AMEN1PGRALDH1A1KDM4E | |
| SCHEMBL5164257 | 0.83 | MEN1 (0.50) | KMT2AMEN1PGRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2012-01-12 | — | — | US | claimed |
| EP-2376456-A2 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group Ptc Ehf (IS) | 2011-10-19 | — | — | EP | claimed |
| WO-2010070449-A2 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-06-24 | — | — | WO | claimed |
| US-12208091-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | ACTIVE BIOTECH AB (SE) | 2025-01-28 | — | — | US | disclosed |
| US-20230066364-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | ACTIVE BIOTECH AB (SE) | 2023-03-02 | — | — | US | disclosed |
| EP-4094765-A1 | COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION | Active Biotech AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| US-11478465-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | ACTIVE BIOTECH AB (SE) | 2022-10-25 | — | — | US | disclosed |
| CN-114845718-A | Compounds for the treatment of ocular diseases associated with excessive vascularization | 活跃生物技术有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20210322400-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | ACTIVE BIOTECH AB (SE) | 2021-10-21 | — | — | US | disclosed |
| EP-3886858-A1 | COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION | Active Biotech AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021123142-A1 | COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION | ACTIVE BIOTECH AB (SE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2010070449-A2 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070449-A2 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070449-A2 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-06-24 | — | — | WO | disclosed |
| EP-1073639-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | disclosed |
| US-4738971-A | ENHANCED CELL-MEDIATED IMMUNITY; ANTIARTHRITIC AGENTS; NONTOXIC | AKTIEBOLASET LEO (SE) | 1988-04-19 | — | — | US | disclosed |
| US-4547511-A | FOR ENHANCIN CELL-MEDIATED IMMUNITY | AKTIEBOLAGET LEO (SE) | 1985-10-15 | — | — | US | disclosed |
| EP-0059698-B1 | HETEROCYCLIC CARBOXAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND METHODS OF TREATMENT THEREWITH | AB LEO (SE) | 1985-09-25 | — | — | EP | disclosed |
| EP-0059698-A1 | Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith | AB LEO (SE) | 1982-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066364-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | CRYAB, ALDH1A2, VEGFA | KMT2A 4310/4885MEN1 3601/4885PGR 2564/4885 |
| US-20210322400-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | CRYAB, ALDH1A2, VEGFA | KMT2A 4310/4885MEN1 3601/4885PGR 2564/4885 |
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TLR7, MYD88, PDE7A | KMT2A 237/4885MEN1 3210/4885PGR 4287/4885 |
| US-12208091-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | CRYAB, ALDH1A2, VEGFA | KMT2A 4310/4885MEN1 3601/4885PGR 2564/4885 |
| US-11478465-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | CRYAB, ALDH1A2, VEGFA | KMT2A 4310/4885MEN1 3601/4885PGR 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.